SEC v. Maurizio Chiriva-Internati

Maurizio Chiriva-Internati allegedly failed to disclose material information about Kiromic’s two cancer fighting drug candidates before, during, and after a July 2, 2021 follow-on public offering that raised $40 million. According to the SEC’s complaint, Kiromic did not disclose the FDA clinical holds in its SEC filings, investor roadshow calls, or during due diligence calls leading up to the offering. The SEC’s complaint alleges that Chiriva reviewed, signed, and contributed content to a report filed with the SEC on June 25, 2021, and signed and certified another report filed with the SEC on August 13, 2021, both of which failed to disclose the FDA clinical holds.

Summary generated from official Securities and Exchange Commission press release